GOVX
GeoVax Labs, Inc.0.2865
-0.0466-14%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
8.61MP/E (TTM)
-Basic EPS (TTM)
-1.27Dividend Yield
0%Recent Filings
8-K
8-K
Nasdaq bid price deficiency
GeoVax Labs received a Nasdaq deficiency notice on July 31, 2025, for its common stock's closing bid price lingering below $1.00 over 30 consecutive business days, breaching the minimum listing rule. The company has until January 27, 2026, to lift the price above $1.00 for 10 straight business days and regain compliance. Nasdaq listing remains intact for now. Delisting looms if they fail, potentially via reverse stock split.
8-K
GeoVax Q2 loss, pipeline advances
GeoVax Labs reported a Q2 2025 net loss of $5.4 million, or $0.35 per share, amid $852 thousand in government contract revenue from its BARDA award, which was terminated for convenience. Yet clinical progress shone: EMA guidance cleared a streamlined Phase 3 path for GEO-MVA mpox/smallpox vaccine, starting 2H 2026, while GEO-CM04S1 showed superior T-cell responses in CLL patients versus mRNA vaccines. Cash dipped to $3.1 million, bolstered by $5.6 million from a July offering. BARDA termination risks funding continuity.
10-Q
Q2 FY2025 results
GeoVax Labs posted Q2 revenue of $852K from its government contract, up sharply from $301K a year ago, while YTD revenue hit $2.5M versus $301K last year—yet the BARDA deal ended abruptly in April for convenience. Operating losses widened to $5.4M from $5.1M y/y, driven by higher R&D on Gedeptin and GEO-MVA programs, with net loss at $5.4M or $0.35 per share on 15.4M weighted shares; YTD, losses narrowed slightly to $10.7M from $10.9M, EPS improving to $(0.79) from $(4.68) thanks to share issuances. Cash burned to $3.1M by quarter-end after $7.9M raised via offerings, with free cash flow negative at $(10.3M) from operations minus minimal capex. Stockholders approved a new incentive plan in June. BARDA termination stings, but clinical momentum builds.
8-K
GeoVax raises $6M in unit offering
GeoVax Labs closed a public offering on July 2, 2025, issuing 9.2 million common units at $0.65 each, including shares and warrants to buy 18.5 million more shares at the same price over five years. Net proceeds of about $5.6 million will fund working capital and corporate needs, while a 60-day lockup bars new stock issuances and a six-month ban hits variable-rate deals. Fresh cash bolsters the biotech's runway amid clinical trials. Warrants add upside, but dilution looms large.
BVAXD
BioVaxys Technology Corp.
0.15-0.03
CVAC
CureVac N.V.
4.82-0.18
INO
Inovio Pharmaceuticals, Inc.
2.32+0.06
MRNA
Moderna, Inc.
29.89-0.03
NNVC
NanoViricides, Inc.
1.29+0.06
NVAX
Novavax, Inc.
6.54-0.04
VIR
Vir Biotechnology, Inc.
6.48-0.24
VIRX
Viracta Therapeutics, Inc.
0.01+0.00
VRAX
Virax Biolabs Group Limited
0.40-0.01
VXRT
Vaxart, Inc.
0.37+0.01